JP2012503010A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012503010A5 JP2012503010A5 JP2011527995A JP2011527995A JP2012503010A5 JP 2012503010 A5 JP2012503010 A5 JP 2012503010A5 JP 2011527995 A JP2011527995 A JP 2011527995A JP 2011527995 A JP2011527995 A JP 2011527995A JP 2012503010 A5 JP2012503010 A5 JP 2012503010A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- compared
- group
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 33
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 6
- 102000001708 Protein Isoforms Human genes 0.000 claims 6
- 108010029485 Protein Isoforms Proteins 0.000 claims 6
- 229910052805 deuterium Inorganic materials 0.000 claims 6
- 102000018832 Cytochromes Human genes 0.000 claims 4
- 108010052832 Cytochromes Proteins 0.000 claims 4
- 102000010909 Monoamine Oxidase Human genes 0.000 claims 4
- 108010062431 Monoamine oxidase Proteins 0.000 claims 4
- 230000036470 plasma concentration Effects 0.000 claims 4
- 230000005764 inhibitory process Effects 0.000 claims 3
- 239000002207 metabolite Substances 0.000 claims 3
- 108010082126 Alanine transaminase Proteins 0.000 claims 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 claims 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 claims 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 claims 2
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 claims 2
- 108010000561 Cytochrome P-450 CYP2C8 Proteins 0.000 claims 2
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 claims 2
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 claims 2
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 claims 2
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 claims 2
- 102100029359 Cytochrome P450 2C8 Human genes 0.000 claims 2
- 102100029358 Cytochrome P450 2C9 Human genes 0.000 claims 2
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 claims 2
- 108010022037 Retinoic Acid 4-Hydroxylase Proteins 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 102100027518 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial Human genes 0.000 claims 1
- 108010073030 25-Hydroxyvitamin D3 1-alpha-Hydroxylase Proteins 0.000 claims 1
- 102100036285 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial Human genes 0.000 claims 1
- 102000004008 5'-Nucleotidase Human genes 0.000 claims 1
- 102100032645 7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase Human genes 0.000 claims 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 claims 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims 1
- 108010078554 Aromatase Proteins 0.000 claims 1
- 102100029361 Aromatase Human genes 0.000 claims 1
- 101000856500 Bacillus subtilis subsp. natto Glutathione hydrolase proenzyme Proteins 0.000 claims 1
- 102000004506 Blood Proteins Human genes 0.000 claims 1
- 108010017384 Blood Proteins Proteins 0.000 claims 1
- 101150051438 CYP gene Proteins 0.000 claims 1
- -1 CYP39 Proteins 0.000 claims 1
- 108010084976 Cholesterol Side-Chain Cleavage Enzyme Proteins 0.000 claims 1
- 102100027516 Cholesterol side-chain cleavage enzyme, mitochondrial Human genes 0.000 claims 1
- 108010009911 Cytochrome P-450 CYP11B2 Proteins 0.000 claims 1
- 108010074918 Cytochrome P-450 CYP1A1 Proteins 0.000 claims 1
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 claims 1
- 108010020070 Cytochrome P-450 CYP2B6 Proteins 0.000 claims 1
- 108010001202 Cytochrome P-450 CYP2E1 Proteins 0.000 claims 1
- 102100024332 Cytochrome P450 11B1, mitochondrial Human genes 0.000 claims 1
- 102100024329 Cytochrome P450 11B2, mitochondrial Human genes 0.000 claims 1
- 102100031476 Cytochrome P450 1A1 Human genes 0.000 claims 1
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 claims 1
- 102100027417 Cytochrome P450 1B1 Human genes 0.000 claims 1
- 102100039282 Cytochrome P450 26A1 Human genes 0.000 claims 1
- 102100039281 Cytochrome P450 26B1 Human genes 0.000 claims 1
- 102100038742 Cytochrome P450 2A13 Human genes 0.000 claims 1
- 102100036194 Cytochrome P450 2A6 Human genes 0.000 claims 1
- 102100038739 Cytochrome P450 2B6 Human genes 0.000 claims 1
- 102100029368 Cytochrome P450 2C18 Human genes 0.000 claims 1
- 102100024889 Cytochrome P450 2E1 Human genes 0.000 claims 1
- 102100031461 Cytochrome P450 2J2 Human genes 0.000 claims 1
- 102100026515 Cytochrome P450 2S1 Human genes 0.000 claims 1
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 claims 1
- 102100039208 Cytochrome P450 3A5 Human genes 0.000 claims 1
- 102100039203 Cytochrome P450 3A7 Human genes 0.000 claims 1
- 102100027567 Cytochrome P450 4A11 Human genes 0.000 claims 1
- 102100027419 Cytochrome P450 4B1 Human genes 0.000 claims 1
- 102100024916 Cytochrome P450 4F11 Human genes 0.000 claims 1
- 102100024918 Cytochrome P450 4F12 Human genes 0.000 claims 1
- 102100024902 Cytochrome P450 4F2 Human genes 0.000 claims 1
- 102100024901 Cytochrome P450 4F3 Human genes 0.000 claims 1
- 102100024899 Cytochrome P450 4F8 Human genes 0.000 claims 1
- 102100022027 Cytochrome P450 4X1 Human genes 0.000 claims 1
- 102100022034 Cytochrome P450 4Z1 Human genes 0.000 claims 1
- 102100038637 Cytochrome P450 7A1 Human genes 0.000 claims 1
- 102100038698 Cytochrome P450 7B1 Human genes 0.000 claims 1
- 108010036233 Cytochrome P450 Family 46 Proteins 0.000 claims 1
- 102000023526 Cytochrome P450 Family 46 Human genes 0.000 claims 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 claims 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 claims 1
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 claims 1
- 101000861278 Homo sapiens 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial Proteins 0.000 claims 1
- 101000725164 Homo sapiens Cytochrome P450 1B1 Proteins 0.000 claims 1
- 101000957389 Homo sapiens Cytochrome P450 2A13 Proteins 0.000 claims 1
- 101000875170 Homo sapiens Cytochrome P450 2A6 Proteins 0.000 claims 1
- 101000919360 Homo sapiens Cytochrome P450 2C18 Proteins 0.000 claims 1
- 101000941723 Homo sapiens Cytochrome P450 2J2 Proteins 0.000 claims 1
- 101000855328 Homo sapiens Cytochrome P450 2S1 Proteins 0.000 claims 1
- 101000745715 Homo sapiens Cytochrome P450 3A7 Proteins 0.000 claims 1
- 101000725111 Homo sapiens Cytochrome P450 4A11 Proteins 0.000 claims 1
- 101000909111 Homo sapiens Cytochrome P450 4F11 Proteins 0.000 claims 1
- 101000909108 Homo sapiens Cytochrome P450 4F12 Proteins 0.000 claims 1
- 101000909122 Homo sapiens Cytochrome P450 4F2 Proteins 0.000 claims 1
- 101000909121 Homo sapiens Cytochrome P450 4F3 Proteins 0.000 claims 1
- 101000909112 Homo sapiens Cytochrome P450 4F8 Proteins 0.000 claims 1
- 101000896935 Homo sapiens Cytochrome P450 4Z1 Proteins 0.000 claims 1
- 101000957672 Homo sapiens Cytochrome P450 7A1 Proteins 0.000 claims 1
- 101000957674 Homo sapiens Cytochrome P450 7B1 Proteins 0.000 claims 1
- 101000875401 Homo sapiens Sterol 26-hydroxylase, mitochondrial Proteins 0.000 claims 1
- 101000653005 Homo sapiens Thromboxane-A synthase Proteins 0.000 claims 1
- 101000855326 Homo sapiens Vitamin D 25-hydroxylase Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 1
- 102100021695 Lanosterol 14-alpha demethylase Human genes 0.000 claims 1
- 101710146773 Lanosterol 14-alpha demethylase Proteins 0.000 claims 1
- 102000002704 Leucyl aminopeptidase Human genes 0.000 claims 1
- 108010004098 Leucyl aminopeptidase Proteins 0.000 claims 1
- 101150053185 P450 gene Proteins 0.000 claims 1
- 108090000279 Peptidyltransferases Proteins 0.000 claims 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 claims 1
- 102100033075 Prostacyclin synthase Human genes 0.000 claims 1
- 102100026372 Putative inactive cytochrome P450 2G1 Human genes 0.000 claims 1
- 108010049356 Steroid 11-beta-Hydroxylase Proteins 0.000 claims 1
- 108010058254 Steroid 12-alpha-Hydroxylase Proteins 0.000 claims 1
- 108010015330 Steroid 17-alpha-Hydroxylase Proteins 0.000 claims 1
- 102100021719 Steroid 17-alpha-hydroxylase/17,20 lyase Human genes 0.000 claims 1
- 102100036325 Sterol 26-hydroxylase, mitochondrial Human genes 0.000 claims 1
- 102100030973 Thromboxane-A synthase Human genes 0.000 claims 1
- 102100026523 Vitamin D 25-hydroxylase Human genes 0.000 claims 1
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- 108010026647 cytochrome P-450 4X1 Proteins 0.000 claims 1
- 108010062869 cytochrome P-450 CYP2G1 Proteins 0.000 claims 1
- 108010018719 cytochrome P-450 CYP4B1 Proteins 0.000 claims 1
- 230000006866 deterioration Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 238000012317 liver biopsy Methods 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108010064377 prostacyclin synthetase Proteins 0.000 claims 1
- 108010043671 prostatic acid phosphatase Proteins 0.000 claims 1
- 238000002604 ultrasonography Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9789608P | 2008-09-18 | 2008-09-18 | |
| US61/097,896 | 2008-09-18 | ||
| PCT/US2009/057480 WO2010044981A2 (en) | 2008-09-18 | 2009-09-18 | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014185634A Division JP5970037B2 (ja) | 2008-09-18 | 2014-09-11 | 小胞モノアミン輸送体２のベンゾキノリン阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012503010A JP2012503010A (ja) | 2012-02-02 |
| JP2012503010A5 true JP2012503010A5 (enExample) | 2012-11-01 |
| JP5616345B2 JP5616345B2 (ja) | 2014-10-29 |
Family
ID=42107127
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011527995A Active JP5616345B2 (ja) | 2008-09-18 | 2009-09-18 | 小胞モノアミン輸送体２のベンゾキノリン阻害剤 |
| JP2014185634A Active JP5970037B2 (ja) | 2008-09-18 | 2014-09-11 | 小胞モノアミン輸送体２のベンゾキノリン阻害剤 |
| JP2016136178A Active JP6138322B2 (ja) | 2008-09-18 | 2016-07-08 | 小胞モノアミン輸送体２のベンゾキノリン阻害剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014185634A Active JP5970037B2 (ja) | 2008-09-18 | 2014-09-11 | 小胞モノアミン輸送体２のベンゾキノリン阻害剤 |
| JP2016136178A Active JP6138322B2 (ja) | 2008-09-18 | 2016-07-08 | 小胞モノアミン輸送体２のベンゾキノリン阻害剤 |
Country Status (20)
| Country | Link |
|---|---|
| US (16) | US8524733B2 (enExample) |
| EP (4) | EP3345905B1 (enExample) |
| JP (3) | JP5616345B2 (enExample) |
| CN (2) | CN104311552A (enExample) |
| AU (1) | AU2009303758B8 (enExample) |
| BR (1) | BRPI0913457B8 (enExample) |
| CA (2) | CA2736409C (enExample) |
| CY (1) | CY1120060T1 (enExample) |
| DK (2) | DK2326643T3 (enExample) |
| ES (4) | ES2425623T3 (enExample) |
| HR (1) | HRP20180239T1 (enExample) |
| HU (1) | HUE038158T2 (enExample) |
| LT (1) | LT3061760T (enExample) |
| NO (1) | NO3061760T3 (enExample) |
| NZ (1) | NZ591615A (enExample) |
| PL (1) | PL3061760T3 (enExample) |
| PT (1) | PT3061760T (enExample) |
| SI (1) | SI3061760T1 (enExample) |
| SM (1) | SMT201800067T1 (enExample) |
| WO (1) | WO2010044981A2 (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3345905B1 (en) | 2008-09-18 | 2021-09-01 | Auspex Pharmaceuticals, Inc. | Deuterated benzoquinolizine derivatives as inhibitors of vesicular monoamine transporter 2 |
| CN102695708B (zh) * | 2009-11-10 | 2014-10-15 | 辉瑞大药厂 | N1-吡唑并螺酮乙酰辅酶a羧化酶抑制剂 |
| WO2011153157A2 (en) * | 2010-06-01 | 2011-12-08 | Auspex Pharmaceutical, Inc. | Benzoquinolone inhibitors of vmat2 |
| US9572880B2 (en) | 2010-08-27 | 2017-02-21 | Sienna Biopharmaceuticals, Inc. | Ultrasound delivery of nanoparticles |
| EP2608762B2 (en) | 2010-08-27 | 2020-05-13 | Sienna Biopharmaceuticals, Inc. | Compositions and methods for targeted thermomodulation |
| WO2012081031A1 (en) | 2010-12-15 | 2012-06-21 | Enaltec Labs Pvt. Ltd. | Process for preparing tetrabenazine |
| EP2897615A4 (en) | 2012-09-18 | 2016-04-27 | Auspex Pharmaceuticals Inc | PHARMACOKINETIC FORMULATIONS OF DEUTERATED BENZOCHINOL INHIBITORS OF THE VESICLE MONOAMINE TRANSPORTER 2 |
| US9550780B2 (en) | 2012-09-18 | 2017-01-24 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| CN104822412B (zh) | 2012-10-11 | 2018-05-01 | 纳诺康波西克斯公司 | 银纳米片组合物及方法 |
| US20160068526A1 (en) * | 2013-01-31 | 2016-03-10 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
| WO2015048370A1 (en) * | 2013-09-27 | 2015-04-02 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
| JP2017503756A (ja) * | 2013-11-22 | 2017-02-02 | オースペックス ファーマシューティカルズ インコーポレイテッド | 異常な筋活動を処置する方法 |
| WO2015077521A1 (en) * | 2013-11-22 | 2015-05-28 | Auspex Pharmaceuticals, Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| EP3424504A1 (en) * | 2013-12-03 | 2019-01-09 | Auspex Pharmaceuticals, Inc. | Methods of manufacturing benzoquinoline compounds |
| MX2016009817A (es) * | 2014-01-27 | 2017-02-28 | Auspex Pharmaceuticals Inc | Inhibidores de benzoquinolina del transportador vesicular de monoaminas 2. |
| WO2015120110A2 (en) | 2014-02-07 | 2015-08-13 | Auspex Pharmaceuticals, Inc. | Novel pharmaceutical formulations |
| WO2015120317A1 (en) | 2014-02-07 | 2015-08-13 | Neurocrine Biosciences, Inc. | Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof |
| KR20240011255A (ko) | 2014-05-06 | 2024-01-25 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 과다운동성 운동 장애의 치료를 위한 vmat2 억제제 |
| MA41557A (fr) * | 2015-02-18 | 2017-12-26 | Auspex Pharmaceuticals Inc | Inhibiteurs diméthoxyphényles du transporteur vésiculaire des monoamines 2 |
| WO2016144901A1 (en) * | 2015-03-06 | 2016-09-15 | Auspex Pharmaceuticals, Inc. | Methods for the treatment of abnormal involuntary movement disorders |
| US20180071024A1 (en) * | 2015-03-20 | 2018-03-15 | Sienna Biopharmaceuticals, Inc. | Enhanced efficacy and targeted topical delivery of drugs to skin with nanoparticles |
| CN115304596A (zh) | 2015-10-30 | 2022-11-08 | 纽罗克里生物科学有限公司 | Valbenazine盐及其多晶形物 |
| SI3394057T1 (sl) | 2015-12-23 | 2022-06-30 | Neurocrine Biosciences, Inc. | Sintetičen postopek za pripravo (S)-(2R,3R,11bR)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1H- pirido(2,1,-a)izokinolin-2-il 2-amino-3-metilbutanoat di(4-metilbenzensulfonata) |
| WO2017182916A1 (en) | 2016-04-22 | 2017-10-26 | Lupin Limited | Novel process for preparation of tetrabenazine and deutetrabenazine |
| WO2017221169A1 (en) | 2016-06-24 | 2017-12-28 | Lupin Limited | Premixes of deutetrabenazine |
| CN107936008B (zh) * | 2016-10-13 | 2022-06-14 | 泰州华元医药科技有限公司 | 氘代化合物及其医药用途 |
| WO2018102673A1 (en) | 2016-12-02 | 2018-06-07 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating schizophrenia or schizoaffective disorder |
| WO2018130345A1 (en) | 2017-01-10 | 2018-07-19 | Sandoz Ag | Crystalline valbenazine free base |
| MY199695A (en) | 2017-01-27 | 2023-11-18 | Neurocrine Biosciences Inc | Methods for the administration of certain vmat2 inhibitors |
| WO2018153632A1 (en) | 2017-02-27 | 2018-08-30 | Sandoz Ag | Crystalline forms of valbenazine salts |
| WO2018164996A1 (en) | 2017-03-06 | 2018-09-13 | Neurocrine Biosciences, Inc. | Dosing regimen for valbenazine |
| KR20230003308A (ko) * | 2017-03-15 | 2023-01-05 | 오스펙스 파마슈티칼스, 인코포레이티드 | 듀테트라베나진의 유사체, 이의 제조 및 용도 |
| JOP20190239A1 (ar) | 2017-04-19 | 2019-10-09 | Neurocrine Biosciences Inc | مركبات مثبطة لـ vmat2 وتركيبات منها |
| WO2018200605A1 (en) | 2017-04-26 | 2018-11-01 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating levodopa-induced dyskinesia |
| DK3684333T3 (da) | 2017-09-21 | 2025-05-12 | Neurocrine Biosciences Inc | Valbenazin-formulering med høj dosis og sammensætninger, fremgangsmåder og kits relateret hertil |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| US10786495B2 (en) * | 2017-10-10 | 2020-09-29 | The Regents Of The University Of California | Vesicular monoamine transporter 2 inhibitors for treating stuttering |
| US20200230127A1 (en) | 2017-10-10 | 2020-07-23 | Neurocrine Biosciences, Inc. | Methods for the Administration of Certain VMAT2 Inhibitors |
| WO2019130252A2 (en) | 2017-12-29 | 2019-07-04 | Mylan Laboratories Ltd | Methods and intermediates for preparing deutetrabenazine |
| EP3749290A4 (en) | 2018-01-29 | 2022-01-26 | Jonathan Sackner-Bernstein | METHODS OF DOPAMINE MODULATION IN HUMAN NEUROLOGICAL DISEASES |
| US11505549B2 (en) * | 2018-02-01 | 2022-11-22 | Lakshmi Prasad ALAPARTHI | Process for preparation of Deutetrabenazine |
| WO2019166962A1 (en) | 2018-03-01 | 2019-09-06 | Mylan Laboratories Ltd | Deutetrabenazine polymorphs and methods for their preparation |
| AU2019261403B2 (en) | 2018-04-25 | 2025-05-15 | Shinkei Therapeutics, Inc. | Tetrabenazine transdermal delivery device |
| US10632107B2 (en) | 2018-05-14 | 2020-04-28 | Apotex Inc. | Crystalline forms of benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| MX2020013004A (es) | 2018-06-14 | 2021-02-17 | Neurocrine Biosciences Inc | Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos. |
| CN108794337A (zh) * | 2018-07-10 | 2018-11-13 | 上海华堇生物技术有限责任公司 | 一种3,4-二羟基-β-硝基苯乙烯的新制备方法 |
| BR112021000019A2 (pt) | 2018-08-15 | 2021-04-06 | Neurocrine Biosciences Inc. | Métodos para administração de certos inibidores de vmat2 |
| CA3116198A1 (en) | 2018-10-18 | 2020-04-23 | Oncopeptides Ab | Compounds containing deuterium |
| BR112021011386A2 (pt) | 2018-12-13 | 2021-08-31 | Auspex Pharmaceuticals, Inc | Deutetrabenazina para o tratamento da discinesia na paralisia cerebral |
| US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
| KR20240025706A (ko) | 2020-06-10 | 2024-02-27 | 오스펙스 파마슈티칼스, 인코포레이티드 | 듀테트라베나진을 포함하는 삼투성 제형 및 이의 사용 방법 |
| EP4213812A1 (en) * | 2020-09-17 | 2023-07-26 | Auspex Pharmaceuticals, Inc. | Multiparticulate dosage forms comprising deutetrabenazine |
| AU2021362683A1 (en) | 2020-10-12 | 2023-06-01 | Auspex Pharmaceuticals Llc | Gastro retentive dosage forms comprising deutetrabenazine |
| AR125188A1 (es) | 2021-03-22 | 2023-06-21 | Neurocrine Biosciences Inc | Inhibidores del vmat2 y métodos de uso |
| EP4362944A1 (en) | 2021-06-30 | 2024-05-08 | Neurocrine Biosciences, Inc. | Valbenazine for use in the add-on treatment of schizophrenia |
| KR20240055160A (ko) | 2021-09-17 | 2024-04-26 | 오스펙스 파마슈티칼스, 인코포레이티드 | 듀테트라베나진을 포함하는 다중미립자 제형 |
| CN119032094A (zh) | 2022-01-05 | 2024-11-26 | K36治疗股份有限公司 | 氘富集的哌啶基-甲基-嘌呤胺和有关化合物及其在治疗疾病和病症中的用途 |
| IL315181A (en) | 2022-03-07 | 2024-10-01 | Neurocrine Biosciences Inc | Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease |
| WO2023240186A1 (en) | 2022-06-08 | 2023-12-14 | Auspex Pharmaceuticals, Inc. | Osmotic dosage forms comprising deutetrabenazine and methods of use thereof |
| WO2025038959A1 (en) | 2023-08-17 | 2025-02-20 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
| WO2025038938A1 (en) | 2023-08-17 | 2025-02-20 | Neurocrine Biosciences, Inc. | Valbenazine for use in the treatment of huntington's chorea |
| WO2025096823A1 (en) | 2023-11-01 | 2025-05-08 | Neurocrine Biosciences, Inc. | Improvement, maintenance or reduction of decline of motor function associated with huntington disease using valbenazine |
| WO2025259267A1 (en) | 2024-06-11 | 2025-12-18 | Vector Vitale Ip Llc | Pharmaceutical compositions for modulating inflammation and oxidative stress comprising chemically enriched elements |
| WO2026050236A1 (en) | 2024-08-27 | 2026-03-05 | Neurocrine Biosciences, Inc. | Muscarinic receptor agonist in combination with a vesicular monoamine transporter 2 inhibitor, for use in the treatment of a neurological or psychiatric disorder |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2830993A (en) * | 1958-04-15 | Quinolizine derivatives | ||
| US3045021A (en) | 1959-09-24 | 1962-07-17 | Hoffmann La Roche | Preparation of substituted 2-oxobenzoquinolizines |
| AT238201B (de) * | 1961-03-28 | 1965-01-25 | Mta | Verfahren zur Herstellung von Chinolizinderivaten |
| US4316897A (en) * | 1980-09-10 | 1982-02-23 | Hoffmann-La Roche Inc. | Method of lowering serum prolactin |
| ES2293638T3 (es) * | 1994-03-25 | 2008-03-16 | Isotechnika, Inc. | Mejora de la eficacia de farmacos por deuteracion. |
| US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US6440710B1 (en) * | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| EP1104760B1 (en) * | 1999-12-03 | 2003-03-12 | Pfizer Products Inc. | Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents |
| EP1134290A3 (en) * | 2000-03-14 | 2004-01-02 | Pfizer Products Inc. | Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors |
| TW200413273A (en) * | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| CA2546395A1 (en) * | 2003-11-21 | 2005-06-09 | Memory Pharmaceutical Corporation | Compositions and methods of treatment using l-type calcium channel blockers and cholinesterase inhibitors |
| GB2410947B (en) * | 2004-02-11 | 2008-09-17 | Cambridge Lab Ltd | Pharmaceutical compounds |
| WO2006053067A2 (en) | 2004-11-09 | 2006-05-18 | Prestwick Pharmaceuticals, Inc. | Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders |
| CN101115761B (zh) | 2005-01-19 | 2012-07-18 | 里格尔药品股份有限公司 | 2,4-嘧啶二胺化合物的前药及其应用 |
| US20080033011A1 (en) * | 2005-07-29 | 2008-02-07 | Concert Pharmaceuticals Inc. | Novel benzo[d][1,3]-dioxol derivatives |
| US7750168B2 (en) * | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| EP2604290A3 (en) | 2006-05-02 | 2013-07-10 | The Trustees of The University of Pennsylvania | Radiolabeled dihydrotetrabenazine derivatives and their use as imaging agents |
| EP2081929B1 (en) | 2006-11-08 | 2013-01-09 | Neurocrine Biosciences, Inc. | Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto |
| EP2420505A1 (en) | 2006-11-21 | 2012-02-22 | Rigel Pharmaceuticals, Inc. | Prodrug salts of 2, 4- pyrimidinediamine compounds and their uses |
| WO2008112278A2 (en) | 2007-03-12 | 2008-09-18 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for modulating insulin secretion and glucose metabolism |
| US8008500B2 (en) * | 2007-06-08 | 2011-08-30 | General Electric Company | Intermediates useful for making tetrabenazine compounds |
| JP5582535B2 (ja) | 2007-06-29 | 2014-09-03 | クラレンス ピーティーワイ エルティーディー | 点眼投与による神経疾患または精神神経疾患の治療または予防 |
| WO2009124357A1 (en) | 2008-04-10 | 2009-10-15 | Malvin Leonard Eutick | Fast dissolving oral formulations for critical drugs |
| WO2011019956A2 (en) | 2009-08-12 | 2011-02-17 | Biovail Laboratories International (Barbados) S.R.L. | Pharmaceutical compositions |
| GB2462611A (en) | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
| EP3345905B1 (en) * | 2008-09-18 | 2021-09-01 | Auspex Pharmaceuticals, Inc. | Deuterated benzoquinolizine derivatives as inhibitors of vesicular monoamine transporter 2 |
| US20100113496A1 (en) * | 2008-09-25 | 2010-05-06 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of vmat2 |
| BR112012020585A2 (pt) | 2010-02-24 | 2018-04-17 | Auspex Pharmaceuticals Inc | composto, composição farmacêutica e método de tratamento de um distúrbio mediado por tirosina quinase |
| WO2011153157A2 (en) * | 2010-06-01 | 2011-12-08 | Auspex Pharmaceutical, Inc. | Benzoquinolone inhibitors of vmat2 |
-
2009
- 2009-09-18 EP EP17199778.6A patent/EP3345905B1/en active Active
- 2009-09-18 PT PT151855483T patent/PT3061760T/pt unknown
- 2009-09-18 NO NO15185548A patent/NO3061760T3/no unknown
- 2009-09-18 CA CA2736409A patent/CA2736409C/en active Active
- 2009-09-18 DK DK09820972.9T patent/DK2326643T3/da active
- 2009-09-18 EP EP09820972.9A patent/EP2326643B1/en active Active
- 2009-09-18 SM SM20180067T patent/SMT201800067T1/it unknown
- 2009-09-18 DK DK15185548.3T patent/DK3061760T3/en active
- 2009-09-18 ES ES09820972T patent/ES2425623T3/es active Active
- 2009-09-18 JP JP2011527995A patent/JP5616345B2/ja active Active
- 2009-09-18 WO PCT/US2009/057480 patent/WO2010044981A2/en not_active Ceased
- 2009-09-18 ES ES17199778T patent/ES2896678T3/es active Active
- 2009-09-18 HU HUE15185548A patent/HUE038158T2/hu unknown
- 2009-09-18 EP EP13160950.5A patent/EP2610254B1/en not_active Not-in-force
- 2009-09-18 PL PL15185548T patent/PL3061760T3/pl unknown
- 2009-09-18 ES ES13160950.5T patent/ES2563820T3/es active Active
- 2009-09-18 BR BRPI0913457A patent/BRPI0913457B8/pt active IP Right Grant
- 2009-09-18 CN CN201410524867.7A patent/CN104311552A/zh active Pending
- 2009-09-18 CN CN200980141378.0A patent/CN102186848B/zh active Active
- 2009-09-18 AU AU2009303758A patent/AU2009303758B8/en active Active
- 2009-09-18 ES ES15185548.3T patent/ES2652289T3/es active Active
- 2009-09-18 NZ NZ591615A patent/NZ591615A/en unknown
- 2009-09-18 US US12/562,621 patent/US8524733B2/en active Active
- 2009-09-18 EP EP15185548.3A patent/EP3061760B1/en active Active
- 2009-09-18 LT LTEP15185548.3T patent/LT3061760T/lt unknown
- 2009-09-18 SI SI200931797T patent/SI3061760T1/en unknown
- 2009-09-18 CA CA2972242A patent/CA2972242A1/en not_active Abandoned
-
2013
- 2013-07-03 US US13/934,960 patent/US20130296360A1/en not_active Abandoned
-
2014
- 2014-03-25 US US14/224,883 patent/US20140206712A1/en not_active Abandoned
- 2014-03-25 US US14/225,010 patent/US20140206713A1/en not_active Abandoned
- 2014-08-08 US US14/454,911 patent/US20140350044A1/en not_active Abandoned
- 2014-09-11 JP JP2014185634A patent/JP5970037B2/ja active Active
- 2014-10-15 US US14/515,047 patent/US20150080427A1/en not_active Abandoned
-
2015
- 2015-07-23 US US14/807,364 patent/US20150328207A1/en not_active Abandoned
-
2016
- 2016-02-11 US US15/041,571 patent/US20160158220A1/en not_active Abandoned
- 2016-04-08 US US15/094,517 patent/US20160220558A1/en not_active Abandoned
- 2016-07-08 JP JP2016136178A patent/JP6138322B2/ja active Active
- 2016-09-01 US US15/254,912 patent/US20160367548A1/en not_active Abandoned
- 2016-09-06 US US15/257,372 patent/US20160375005A1/en not_active Abandoned
-
2017
- 2017-02-28 US US15/445,402 patent/US20170166562A1/en not_active Abandoned
-
2018
- 2018-02-07 CY CY20181100152T patent/CY1120060T1/el unknown
- 2018-02-07 HR HRP20180239TT patent/HRP20180239T1/hr unknown
- 2018-12-05 US US16/210,077 patent/US20190375746A1/en not_active Abandoned
-
2020
- 2020-03-17 US US16/821,067 patent/US20200347048A1/en not_active Abandoned
-
2021
- 2021-11-05 US US17/519,922 patent/US20220267317A1/en not_active Abandoned
-
2025
- 2025-03-17 US US19/081,808 patent/US20250326747A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012503010A5 (enExample) | ||
| JP2012524085A5 (enExample) | ||
| JP2010507585A5 (enExample) | ||
| JP2009511481A5 (enExample) | ||
| ES2633658T3 (es) | Moduladores 2-oxo-1,2-dihidro-quinolina de la función inmunitaria | |
| JP2009539863A5 (enExample) | ||
| JP2009538359A5 (enExample) | ||
| JP2010512343A5 (enExample) | ||
| JP2016529228A5 (enExample) | ||
| US10517860B2 (en) | Combination of pimavanserin and cytochrome P450 modulators | |
| US9526711B2 (en) | Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor | |
| US20180016244A1 (en) | Deuterium-substituted oxadiazoles | |
| US20110206661A1 (en) | Trimethoxyphenyl inhibitors of tyrosine kinase | |
| US20100167989A1 (en) | Isopropoxyphenylmethyl inhibitors of sglt2 | |
| CA2631581A1 (en) | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity | |
| US10953000B2 (en) | Combination of pimavanserin and cytochrome P450 modulators | |
| US20110082151A1 (en) | Sulfonylurea modulators of endothelin receptor | |
| JP2018507210A5 (enExample) | ||
| US20100075950A1 (en) | Phenylpropanone modulators of dopamine receptor | |
| US20100286124A1 (en) | Prop-2-yn-1-amine inhibitors of monoamine oxidase type b | |
| US20110091459A1 (en) | Imidazole modulators of muscarinic acetylcholine receptor m3 | |
| JPWO2020198529A5 (enExample) | ||
| RU2024129873A (ru) | Дейтерированные аналоги пиррольных ингибиторов erk, их синтез и промежуточные соединения | |
| US20100120861A1 (en) | Benzoic acid inhibitors of atp-sensitive potassium channels | |
| US8227451B2 (en) | Phenylacetic acid inhibitors of cyclooxygenase |